Cannabis Sprays for Chronic Pain: Lessons from 34 Individual Patient Trials | Research

The takeaway

In 34 individual patient trials of sublingual cannabis extracts for chronic pain, THC-containing extracts were most effective, with a wide dose range needed and common but generally acceptable side effects.

Read this if you have chronic pain and want practical information about how cannabis-based medicines are dosed.

THC-containing extracts most effective across 34 individual pain trials

What the researchers found

Thirty-four patients with chronic, mainly neuropathic, pain used three cannabis-based sublingual sprays (THC, CBD, and 1:1 THC:CBD) over 12 weeks in individual randomized crossover trials. THC-containing extracts proved most effective for symptom control. A wide range of dosing requirements was observed across patients, and structured regimens for using the sublingual spray emerged from patient experience.

Side effects were common, reflecting a learning curve for both patients and the study team, but were generally acceptable and similar to those seen with other psychoactive medications used for chronic pain. The study established practical parameters for using cannabis-based medicines in pain management.

Why it matters

This study provided practical clinical experience with cannabis-based medicines that was crucial for the development of dosing guidelines. The finding that THC was the primary active ingredient for pain, and that a wide dose range was needed, influenced how Sativex was subsequently prescribed.

The numbers in context

Thirty-four patients studied individually over 12 weeks each. Three extract formulations tested. THC-containing extracts most effective. Wide dosing range observed. Side effects common but generally acceptable.

How the study worked

These were 34 individual "N of 1" trials using sublingual cannabis extracts. After an initial open-label period, the three extracts (THC, CBD, THC:CBD 1:1) were tested in randomized, double-blind, placebo-controlled crossover format over 12 weeks per patient.

What this study cannot tell us

N-of-1 trials, while rigorous for individual patients, have limited generalizability. The open-label period may have biased subsequent randomized periods. Side effects described as "common" raises questions about long-term tolerability.

How to read the evidence

This is a series of randomized, blinded, individual patient trials providing moderate-level evidence with practical clinical detail.

When this study was published

Published in 2004. These early experiences directly informed the development of Sativex dosing guidelines.

The bigger picture

These early clinical experiences with sublingual cannabis extracts directly informed the development and clinical use of Sativex. The individual patient trial design, while unusual, provided detailed data on tolerability and dosing that larger trials could not capture.

Questions still open

Why was CBD alone less effective for pain than THC? Could the wide dosing range be predicted by patient characteristics? How do these results compare to conventional pain medications?

Common questions

Is THC or CBD better for pain?

In these trials, THC-containing extracts were most effective for chronic pain control. CBD alone was less effective for pain, though it may contribute to the overall effect when combined with THC.

Why do people need such different doses?

The wide dosing range observed reflects individual differences in cannabinoid metabolism, receptor sensitivity, pain severity, and tolerance. This is why cannabis-based medications typically require individual dose titration.

Read the original research

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.

Anaesthesia, 59(5), 440-52

View on PubMed ↗

Citation

Notcutt, William; Price, Mario; Miller, Roy; Newport, Samantha; Phillips, Cheryl; Simmons, Susan; Sansom, Cathy. (2004). Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies.. Anaesthesia, 59(5), 440-52.